This Article Full Text Full Text (PDF) All Versions of this Article: 38/12/3186    most recent STROKEAHA.107.492033v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Bär, K.-J. Articles by Sauer, H. Search for Related Content PubMed PubMed Citation Articles by Bär, K.-J. Articles by Sauer, H. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Alzheimer's Disease Hazardous Substances DB CARBON DIOXIDE Related Collections Cerebrovascular disease/stroke CT and MRI Acute Cerebral Hemorrhage Brain Circulation and Metabolism Computerized tomography and Magnetic Resonance Imaging Doppler ultrasound, Transcranial Doppler etc. Other imaging

(Stroke. 2007;38:3186.)
© 2007 American Heart Association, Inc.

Original Contributions

Influence of Galantamine on Vasomotor Reactivity in Alzheimer’s Disease and Vascular Dementia Due to Cerebral Microangiopathy

Karl-Jürgen Bär, MD; Michael Karl Boettger, MD; Nicole Seidler; Hans Joachim Mentzel, MD; Christoph Terborg, MD Heinrich Sauer, MD

From the Department of Psychiatry (K.-J.B., N.S., H.S.), the Institute of Physiology I (M.K.B.), the Institute of Diagnostic and Interventional Radiology (H.J.M.), and the Department of Neurology (C.T.), Friedrich-Schiller-University Jena, Jena, Germany.

Correspondence to Karl-Jürgen Bär, MD, Department of Psychiatry, Friedrich-Schiller-University Jena, Philosophenweg 3, 07743 Jena, Germany. E-mail Karl-Juergen.Baer{at}med.uni-jena.de

Background and Purpose— Recent reports suggest that vascular factors play a crucial role in the development and progression of Alzheimer’s disease. We aimed to assess vasomotor reactivity in patients with Alzheimer’s disease and vascular dementia due to microangiopathy using transcranial Doppler sonography and near-infrared spectroscopy during a CO₂ exposition task.

Methods— The normalized CO₂ reactivity assessed at the middle cerebral artery and the oxygenated and deoxygenated hemoglobin of the frontal cortex were obtained. To investigate the impact of cholinergic deficiency known for Alzheimer’s disease on vasomotor reactivity, both groups were reinvestigated during treatment with the acetylcholine esterase inhibitor galantamine.

Results— Transcranial Doppler analysis revealed significantly reduced normalized CO₂ reactivity for Alzheimer’s disease and vascular dementia. Vasomotor reactivity assessed by near-infrared spectroscopy was decreased in patients with vascular dementia, but not in Alzheimer’s disease. Galantamine treatment showed a beneficial effect, normalizing these parameters close to age-matched control levels.

Conclusions— Our results suggest that Alzheimer’s disease is associated with a lack of vasomotor reactivity, which might be associated with disturbed autoregulation indicating a potential risk for a decreased protection of brain tissue against blood pressure changes. Additionally, a diminished increase of cortical oxygenated hemoglobin during the CO₂ test was apparent in patients with vascular dementia. Galantamine treatment influenced vascular reactivity in the CO₂ test, thus providing evidence for the cholinergic deficiency, thereby adding to vascular dysregulation in Alzheimer’s disease, but also indicating an important role of cholinergic system dysfunction for vascular dementia.

Key Words: autonomic nervous system • Alzheimer’s disease • dementia • near-infrared spectroscopy • transcranial Doppler sonography